Pathogenesis and prevention of immune reconstitution disease during antiretroviral therapy

Expert Review of Anti-Infective Therapy

Volumn 9, Issue 4, 2011, Pages 415-430

  Lawn, Stephen D ^a,b   Meintjes, Graeme ^a,c,d,e  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c UNIVERSITY OF CAPE TOWN   (South Africa)

^d GF Jooste Hospital   (South Africa)

^e IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

antiretroviral; HIV; immune reconstitution; immune reconstitution inflammatory syndrome; IRIS; prevention

Indexed keywords

AMPHOTERICIN B; CORTICOSTEROID; FLUCONAZOLE; ISONIAZID; MARAVIROC; MYCOBACTERIUM ANTIGEN; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PREDNISONE; VITAMIN D; ZIDOVUDINE;

ATYPICAL MYCOBACTERIOSIS; CD4 LYMPHOCYTE COUNT; COST EFFECTIVENESS ANALYSIS; CRYPTOCOCCAL MENINGITIS; CRYPTOCOCCOSIS; CYTOMEGALOVIRUS RETINITIS; DISEASE COURSE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOPATHOGENESIS; IMMUNOREGULATION; INFECTION PREVENTION; NONHUMAN; OPPORTUNISTIC INFECTION; REGULATORY T LYMPHOCYTE; REVIEW; RISK FACTOR; SCREENING; TUBERCULOSIS; VIRUS LOAD;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CLINICAL TRIALS AS TOPIC; HIV; HIV INFECTIONS; HUMANS; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; INCIDENCE; RISK FACTORS; TIME FACTORS; VIRAL LOAD;

EID: 79955083774     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/eri.11.21     Document Type: Review

References (141)

1. Shelburne SA III, Hamill RJ. The immune reconstitution inflammatory syndrome. AIDS Rev. 5, 67-79 (2003).
2. French MA, Price P, Stone SF. Immune restoration disease after antiretroviral therapy. AIDS 18, 1615-1627 (2004). (Pubitemid 39095778)
3. Lawn SD, Bekker LG, Miller RF. Immune reconstitution disease associated with mycobacterial infections in HIV-infected individuals receiving antiretrovirals. Lancet Infect. Dis. 5, 361-373 (2005). (Pubitemid 40779257)
4. Meintjes G, Lawn SD, Scano F et al. Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings. Lancet Infect. Dis. 8, 516-523 (2008). (Pubitemid 352005824)
5. Ustianowski AP, Lawn SD, Lockwood DN. Interactions between HIV infection and leprosy: a paradox. Lancet Infect. Dis. 6, 350-360 (2006). (Pubitemid 43737271)
6. Haddow LJ, Colebunders R, Meintjes G et al. Cryptococcal immune reconstitution inflammatory syndrome in HIV-1-infected individuals: literature review and proposed clinical case definitions. Lancet Infect. Dis. 10, 791-802 (2010).
7. Otiti-Sengeri J, Meenken C, van den Horn GJ, Kempen JH. Ocular immune reconstitution inflammatory syndromes. Curr. Opin. HIV AIDS 3, 432-437 (2008).
8. Bower M, Nelson M, Young AM et al. Immune reconstitution inflammatory syndrome associated with Kaposi's sarcoma. J. Clin. Oncol. 23, 5224-5228 (2005). (Pubitemid 46224033)
9. Tan CS, Koralnik IJ. Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis. Lancet Neurol. 9, 425-437 (2010).
10. Torok ME, Kambugu A, Wright E. Immune reconstitution disease of the central nervous system. Curr. Opin. HIV AIDS 3, 438-445 (2008).
11. Muller M, Wandel S, Colebunders R, Attia S, Furrer H, Egger M. Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: a systematic review and meta-analysis. Lancet Infect. Dis. 10, 251-261 (2010).
12. Phillips P, Bonner S, Gataric N et al. Nontuberculous mycobacterial immune reconstitution syndrome in HIV-infected patients: spectrum of disease and long-term follow-up. Clin. Infect. Dis. 41, 1483-1497 (2005). (Pubitemid 41579994)
13. Lawn SD, Lipman MC, Easterbrook PJ. Immune reconstitution disease associated with mycobacterial infections. Curr. Opin. HIV AIDS 3, 425-431 (2008).
14. Breen RA, Smith CJ, Bettinson H et al. Paradoxical reactions during tuberculosis treatment in patients with and without HIV co-infection. Thorax 59, 704-707 (2004). (Pubitemid 39061536)
15. Lawn SD, Myer L, Bekker LG, Wood R. Tuberculosis-associated immune reconstitution disease: incidence, risk factors and impact in an antiretroviral treatment service in South Africa. AIDS 21, 335-341 (2007). (Pubitemid 46175045)
16. Burman W, Weis S, Vernon A et al. Frequency, severity and duration of immune reconstitution events in HIV-related tuberculosis. Int. J. Tuberc. Lung Dis. 11, 1282-1289 (2007).
17. Navas E, Martin-Davila P, Moreno L et al. Paradoxical reactions of tuberculosis in patients with the acquired immunodeficiency syndrome who are treated with highly active antiretroviral therapy. Arch. Intern. Med. 162, 97-99 (2002). (Pubitemid 34073410)
18. Blanc F-X, Sok T, Laureillard D et al. Significant enhancement in survival with early (2 weeks) vs late (8 weeks) initiation of highly active antiretroviral treatment (HAART) in severely immunosuppressed HIV-infected adults with newly diagnosed tuberculosis. Program and Abstracts of the XVIII International AIDS Conference. Vienna, Austria (2010) (Abstract THLBB1).
19. Abdool Karim SS, Naidoo K, Grobler A et al. Timing of initiation of antiretroviral drugs during tuberculosis therapy. N. Engl. J. Med. 362, 697-706 (2010).
20. Shelburne SA III, Darcourt J, White AC Jr et al. The role of immune reconstitution inflammatory syndrome in AIDS-related Cryptococcus neoformans disease in the era of highly active antiretroviral therapy. Clin. Infect. Dis. 40, 1049-1052 (2005). (Pubitemid 40418316)
21. Lortholary O, Fontanet A, Memain N, Martin A, Sitbon K, Dromer F. Incidence and risk factors of immune reconstitution inflammatory syndrome complicating HIV-associated cryptococcosis in France. AIDS 19, 1043-1049 (2005). (Pubitemid 40961144)
22. Bicanic T, Meintjes G, Rebe K et al. Immune reconstitution inflammatory syndrome in HIV-associated cryptococcal meningitis: a prospective study. J. Acquir. Immune Defic. Syndr. 51, 130-134 (2009).
23. Sungkanuparph S, Filler SG, Chetchotisakd P et al. Cryptococcal immune reconstitution inflammatory syndrome after antiretroviral therapy in AIDS patients with cryptococcal meningitis: a prospective multicenter study. Clin. Infect. Dis. 49, 931-934 (2009).
24. Manosuthi W, Kiertiburanakul S, Phoorisri T, Sungkanuparph S. Immune reconstitution inflammatory syndrome of tuberculosis among HIV-infected patients receiving antituberculous and antiretroviral therapy. J. Infect. 53, 357-363 (2006). (Pubitemid 44688983)
25. Serra FC, Hadad D, Orofino RL et al. Immune reconstitution syndrome in patients treated for HIV and tuberculosis in Rio de Janeiro. Braz. J. Infect. Dis. 11, 462-465 (2007). (Pubitemid 350111043)
26. Breton G, Duval X, Estellat C et al. Determinants of immune reconstitution inflammatory syndrome in HIV type 1-infected patients with tuberculosis after initiation of antiretroviral therapy. Clin. Infect. Dis. 39, 1709-1712 (2004). (Pubitemid 39578550)
27. Michailidis C, Pozniak AL, Mandalia S, Basnayake S, Nelson MR, Gazzard BG. Clinical characteristics of IRIS syndrome in patients with HIV and tuberculosis. Antivir. Ther. 10, 417-422 (2005). (Pubitemid 41151019)
28. Manabe YC, Kesavan AK, Lopez-Molina J et al. The aerosol rabbit model of TB latency, reactivation and immune reconstitution inflammatory syndrome. Tuberculosis (Edinb.) 88, 187-196 (2008).
29. Lawn SD, Edwards DJ, Kranzer K, Vogt M, Bekker LG, Wood R. Urine lipoarabinomannan assay for tuberculosis screening before antiretroviral therapy diagnostic yield and association with immune reconstitution disease. AIDS 23, 1875-1880 (2009).
30. Shah M, Variava E, Holmes CB et al. Diagnostic accuracy of a urine lipoarabinomannan test for tuberculosis in hospitalized patients in a high HIV prevalence setting. J. Acquir. Immune Defic. Syndr. 52, 145-151 (2009).
31. Letang E, Almeida JM, Miro JM et al. Predictors of immune reconstitution inflammatory syndrome-associated with Kaposi sarcoma in mozambique: a prospective study. J. Acquir. Immune Defic. Syndr. 53, 589-597 (2010).
32. Karavellas MP, Lowder CY, Macdonald C, Avila CP Jr, Freeman WR. Immune recovery vitritis associated with inactive cytomegalovirus retinitis: a new syndrome. Arch. Ophthalmol. 116, 169-175 (1998).
33. Manabe YC, Campbell JD, Sydnor E, Moore RD. Immune reconstitution inflammatory syndrome: risk factors and treatment implications. J. Acquir. Immune Defic. Syndr. 46, 456-462 (2007). (Pubitemid 350098697)
34. French MA, Lenzo N, John M et al. Immune restoration disease after the treatment of immunodeficient HIV-infected patients with highly active antiretroviral therapy. HIV Med. 1, 107-115 (2000).
35. Ratnam I, Chiu C, Kandala NB, Easterbrook PJ. Incidence and risk factors for immune reconstitution inflammatory syndrome in an ethnically diverse HIV type 1-infected cohort. Clin. Infect. Dis. 42, 418-427 (2006). (Pubitemid 43122323)
36. Jevtovic DJ, Salemovic D, Ranin J, Pesic I, Zerjav S, Djurkovic-Djakovic O. The prevalence and risk of immune restoration disease in HIV-infected patients treated with highly active antiretroviral therapy. HIV Med. 6, 140-143 (2005). (Pubitemid 40425979)
37. Grant PM, Komarow L, Andersen J et al. Risk factor analyses for immune reconstitution inflammatory syndrome in a randomized study of early vs. deferred ART during an opportunistic infection. PLoS ONE 5, e11416 (2010).
38. Narita M, Ashkin D, Hollender ES, Pitchenik AE. Paradoxical worsening of tuberculosis following antiretroviral therapy in patients with AIDS. Am. J. Respir. Crit. Care Med. 158, 157-161 (1998). (Pubitemid 28337174)
39. Cinque P, Pierotti C, Vigano MG et al. The good and evil of HAART in HIV-related progressive multifocal leukoencephalopathy. J. Neurovirol. 7(4), 358-363 (2001). (Pubitemid 32894242)
40. Shao HJ, Crump JA, Ramadhani HO et al. Early versus delayed fixed dose combination abacavir/lamivudine/zidovudine in patients with HIV and tuberculosis in Tanzania. AIDS Res. Hum. Retroviruses 25, 1277-1285 (2009).
41. Bourgarit A, Carcelain G, Samri A et al. Tuberculosis-associated immune restoration syndrome in HIV-1-infected patients involves tuberculin-specific CD4 Th1 cells and KIR-negative gd T cells. J. Immunol. 183, 3915-3923 (2009).
42. Simonney N, Dewulf G, Herrmann JL et al. Anti-PGL-Tb1 responses as an indicator of the immune restoration syndrome in HIV-TB patients. Tuberculosis (Edinb.) 88, 453-461 (2008).
43. Perrin FM, Breen RA, Lipman MC, Shorten RJ, Gillespie SH, McHugh TD. Is there a relationship between Mycobacterium tuberculosis strain type and TB paradoxical reaction? Thorax 60, 706-707 (2005). (Pubitemid 41129076)
44. Price P, Morahan G, Huang D et al. Polymorphisms in cytokine genes define subpopulations of HIV-1 patients who experienced immune restoration diseases. AIDS 16, 2043-2047 (2002). (Pubitemid 35205268)
45. Price P, Mathiot N, Krueger R, Stone S, Keane NM, French MA. Immune dysfunction and immune restoration disease in HIV patients given highly active antiretroviral therapy. J. Clin. Virol. 22, 279-287 (2001). (Pubitemid 32846559)
46. Conesa-Botella A, Mathieu C, Colebunders R et al. Is vitamin D deficiency involved in the immune reconstitution inflammatory syndrome? AIDS Res. Ther. 6, 4 (2009).
47. Kestens L, Seddiki N, Bohjanen PR. Immunopathogenesis of immune reconstitution disease in HIV patients responding to antiretroviral therapy. Curr. Opin. HIV AIDS 3, 419-424 (2008).
48. French MA, Mallal SA, Dawkins RL. Zidovudine-induced restoration of cell-mediated immunity to mycobacteria in immunodeficient HIV-infected patients. AIDS 6, 1293-1297 (1992).
49. Bourgarit A, Carcelain G, Martinez V et al. Explosion of tuberculin-specific Th1- responses induces immune restoration syndrome in tuberculosis and HIV co-infected patients. AIDS 20, F1-F7 (2006).
50. Elliott JH, Vohith K, Saramony S et al. Immunopathogenesis and diagnosis of tuberculosis and tuberculosis-associated immune reconstitution inflammatory syndrome during early antiretroviral therapy. J. Infect. Dis 200, 1736-1745 (2009).
51. Meintjes G, Wilkinson KA, Rangaka MX et al. Type 1 helper T cells and FoxP3- positive T cells in HIV-tuberculosis-associated immune reconstitution inflammatory syndrome. Am. J. Respir. Crit. Care Med 178, 1083-1089 (2008).
52. Tan DB, Yong YK, Tan HY et al. Immunological profiles of immune restoration disease presenting as mycobacterial lymphadenitis and cryptococcal meningitis. HIV Med. 9, 307-316 (2008). (Pubitemid 351517278)
53. Tieu HV, Ananworanich J, Avihingsanon A et al. Immunologic markers as predictors of tuberculosis-associated immune reconstitution inflammatory syndrome in HIV and tuberculosis coinfected persons in Thailand. AIDS Res. Hum. Retroviruses 25, 1083-1089 (2009).
54. Ruhwald M, Ravn P. Immune reconstitution syndrome in tuberculosis and HIV-co-infected patients: Th1 explosion or cytokine storm? AIDS 21, 882-884 (2007). (Pubitemid 46573166)
55. Tadokera R, Meintjes G, Skolimowska KH et al. Hypercytokinaemia accompanies HIV-tuberculosis immune reconstitution inflammatory syndrome. Eur. Respir. J. DOI: 10.1183/09031936.00091010 (2010) (Epub ahead of print).
56. Lim A, D'Orsogna L, Price P, French MA. Imbalanced effector and regulatory cytokine responses may underlie mycobacterial immune restoration disease. AIDS Res. Ther. 5, 9 (2008).
57. + T-cell responses in HIV-positive patients with mycobacterial immune restoration disease. Eur. J. Immunol. 39, 391-403 (2009).
58. Van den Bergh R, Vanham G, Raes G, De Baetselier P, Colebunders R. Mycobacterium-associated immune reconstitution disease: macrophages running wild? Lancet Infect. Dis. 6, 2-3 (2006).
59. Lawn SD, Wainwright H, Orrell C. Fatal unmasking tuberculosis immune reconstitution disease with bronchiolitis obliterans organizing pneumonia: the role of macrophages. AIDS 23, 143-145 (2009).
60. Oliver BG, Elliott JH, Saphonn V, Vun MC, French MA, Price P. Interferon-γ and IL-5 production correlate directly in HIV patients co-infected with Mycobacterium tuberculosis with or without immune restoration disease. AIDS Res. Hum. Retroviruses 26(12), 1287-1289 (2010).
61. Boulware DR, Bonham SC, Meya DB et al. Paucity of initial cerebrospinal fluid inflammation in cryptococcal meningitis is associated with subsequent immune reconstitution inflammatory syndrome. J. Infect. Dis. 202, 962-970 (2010).
62. Price P, Murdoch DM, Agarwal U, Lewin SR, Elliott JH, French MA. Immune restoration diseases reflect diverse immunopathological mechanisms. Clin. Microbiol. Rev. 22, 651-663 (2009).
63. Leidner RS, Aboulafia DM. Recrudescent Kaposi's sarcoma after initiation of HAART: a manifestation of immune reconstitution syndrome. AIDS Patient Care STDs 19, 635-644 (2005). (Pubitemid 41527674)
64. Mesri EA. Inflammatory reactivation and angiogenicity of Kaposi's sarcoma-associated herpesvirus/HHV8: a missing link in the pathogenesis of acquired immunodeficiency syndrome-associated Kaposi's sarcoma. Blood 93, 4031-4033 (1999). (Pubitemid 29279244)
65. Martin J, Laker M, Clutter D et al. Kaposi's sarcoma-associated IRIS in Africa: initial findings from a prospective evaluation. Program and Abstracts of the 16th Conference on Retroviruses and Opportunistic Infections. Montreal, Canada (2009) (Abstract 31).
66. Schrier RD, Song MK, Smith IL et al. Intraocular viral and immune pathogenesis of immune recovery uveitis in patients with healed cytomegalovirus retinitis. Retina 26, 165-169 (2006). (Pubitemid 44400711)
67. Mutimer HP, Akatsuka Y, Manley T et al. Association between immue recovery uveitis and a diverse intraocular cytomegalovirus-specific cytotoxic T cell response. J. Infect. Dis 186, 701-705 (2002). (Pubitemid 34925544)
68. Stone SF, Price P, Tay-Kearney ML, French MA. Cytomegalovirus (CMV) retinitis immune restoration disease occurs during highly active antiretroviral therapy-induced restoration of CMV-specific immune responses within a predominant Th2 cytokine environment. J. Infect. Dis. 185, 1813-1817 (2002). (Pubitemid 34615479)
69. Sterne JA, May M, Costagliola D et al. Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet 373, 1352-1363 (2009).
70. Lawn SD, Harries AD, Anglaret X, Myer L, Wood R. Early mortality among adults accessing antiretroviral treatment programmes in sub-Saharan Africa. AIDS 22, 1897-1908 (2008).
71. Tuboi SH, Schechter M, McGowan CC et al. Mortality during the first year of potent antiretroviral therapy in HIV-1- infected patients in 7 sites throughout Latin America and the Caribbean. J. Acquir. Immune Defic. Syndr. 51, 615-623 (2009).
72. Chasombat S, McConnell MS, Siangphoe U et al. National expansion of antiretroviral treatment in Thailand, 2000-2007: program scale-up and patient outcomes. J. Acquir. Immune Defic. Syndr. 50, 506-512 (2009).
73. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Department of Health and Human Services, USA, 1-166 (2011).
74. Keiser O, Anastos K, Schechter M et al. Antiretroviral therapy in resource-limited settings 1996 to 2006: patient characteristics, treatment regimens and monitoring in sub-Saharan Africa, Asia and Latin America. Trop. Med. Int. Health 13, 870-879 (2008). (Pubitemid 351813514)
75. Boulle A, Van CG, Hilderbrand K et al. Seven-year experience of a primary care antiretroviral treatment programme in Khayelitsha, South Africa. AIDS 24, 563-572 (2010).
76. Nglazi M, Lawn SD, Kaplan R et al. Changes in programmatic outcomes during 7 years of scale-up at a community-based antiretroviral treatment service in South Africa. J. Acquir. Immune Defic. Syndr. 56, e1-e8 (2011).
77. Battegay M, Fluckiger U, Hirschel B, Furrer H. Late presentation of HIV-infected individuals. Antivir. Ther. 12, 841-851 (2007). (Pubitemid 47492554)
78. Akolo C, Adetifa I, Shepperd S, Volmink J. Treatment of latent tuberculosis infection in HIV-infected persons. Cochrane Database Syst. Rev. DOI: 10.1002/14651858.CD000171.pub2 (2004) (Epub ahead of print).
79. Golub JE, Saraceni V, Cavalcante SC et al. The impact of antiretroviral therapy and isoniazid preventive therapy on tuberculosis incidence in HIV-infected patients in Rio de Janeiro, Brazil. AIDS 21, 1441-1448 (2007). (Pubitemid 46988004)
80. Golub JE, Pronyk P, Mohapi L et al. Isoniazid preventive therapy, HAART and tuberculosis risk in HIV-infected adults in South Africa: a prospective cohort. AIDS 23, 631-636 (2009).
81. Lawn SD, Wood R, De Cock KM, Kranzer K, Lewis JJ, Churchyard GJ. Antiretrovirals and isoniazid preventive therapy in the prevention of HIV-associated tuberculosis in settings with limited health-care resources. Lancet Infect. Dis. 10, 489-498 (2010).
82. World Health Organization. Treatment of Tuberculosis. Guidelines for National Programmes. 3rd Edition. WHO/CDS/TB 2003.313. WHO, Geneva, Switzerland (2003).
83. Getahun H. Meta-analysis to inform the development of a standardised approach for TB screening in HIV-infected patients. Prsented at: 40th Union World Conference on Lung Health, Cancun, Mexico, 3-7 December 2009 (Symposium 2).
84. Cain KP, McCarthy KD, Heilig CM et al. An algorithm for tuberculosis screening and diagnosis in people with HIV. N. Engl. J. Med. 362, 707-716 (2010).
85. Reid MJ, Shah NS. Approaches to tuberculosis screening and diagnosis in people with HIV in resource-limited settings. Lancet Infect. Dis. 9, 173-184 (2009).
86. Getahun H, Kittikraisak W, Heilig CM et al. Development of a standardized screening rule for tuberculosis in people living with HIV in resource-constrained settings: individual participant data meta-analysis of observational studies. PLoS Med. 8(1), e1000391 (2011).
87. Chang LW, Phipps WT, Kennedy GE, Rutherford GW. Antifungal interventions for the primary prevention of cryptococcal disease in adults with HIV. Cochrane Database Syst Rev. 3, CD004773 (2005).
88. Feldmesser M, Harris C, Reichberg S, Khan S, Casadevall A. Serum cryptococcal antigen in patients with AIDS. Clin. Infect. Dis. 23, 827-830 (1996). (Pubitemid 26331133)
89. Scharfstein JA, Paltiel AD, Freedberg KA. The cost-effectiveness of fluconazole prophylaxis against primary systemic fungal infections in AIDS patients. Med. Decis. Making 17, 373-381 (1997). (Pubitemid 27444308)
90. Yazdanpanah Y, Goldie SJ, Paltiel AD et al. Prevention of human immunodeficiency virus-related opportunistic infections in France: a cost-effectiveness analysis. Clin. Infect. Dis. 36, 86-96 (2003). (Pubitemid 36099102)
91. Madec Y, Laureillard D, Pinoges L et al. Response to highly active antiretroviral therapy among severely immuno-compromised HIV-infected patients in Cambodia. AIDS 21, 351-359 (2007). (Pubitemid 46175047)
92. Manosuthi W, Sungkanuparph S, Thongyen S et al. Antifungal susceptibilities of Cryptococcus neoformans cerebrospinal fluid isolates and clinical outcomes of cryptococcal meningitis in HIV-infected patients with/without fluconazole prophylaxis. J. Med. Assoc. Thai. 89, 795-802 (2006). (Pubitemid 44065969)
93. Apisarnthanarak A, Mundy LM. The impact of primary prophylaxis for cryptococcosis on fluconazole resistance in Candida species. J. Acquir. Immune Defic. Syndr. 47, 644-645 (2008). (Pubitemid 351442010)
94. Parkes-Ratanshi R, Kamali A, Wakeham K et al. Successful primary prevention of cryptococcal disease using fluconazole prophylaxis in HIV-infected Ugandan adults. Program and Abstracts of the 16th Conference on Retroviruses and Opportunistic Infections (CROI).Montreal, Canada (2009) (Abstract 32).
95. Jarvis JN, Lawn SD, Vogt M, Bangani N, Wood R, Harrison TS. Screening for cryptococcal antigenemia in patients accessing an antiretroviral treatment program in South Africa. Clin. Infect. Dis. 48, 856-862 (2009).
96. + cell count 100 cells/μl who start HIV therapy in resource-limited settings. Clin. Infect. Dis. 51, 448-455 (2010).
97. Jarvis JN, Meintjes G, Williams Z, Rebe K, Harrison TS. Symptomatic relapse of HIV-associated cryptococcal meningitis in South Africa: the role of inadequate secondary prophylaxis. S. Afr. Med. J. 100, 378-382 (2010).
98. Lawn SD, Myer L, Orrell C, Bekker LG, Wood R. Early mortality among adults accessing a community-based antiretroviral service in South Africa: implications for programme design. AIDS 19, 2141-2148 (2005). (Pubitemid 41669003)
99. Lawn SD, Bekker LG, Myer L, Orrell C, Wood R. Cryptococcocal immune reconstitution disease: a major cause of early mortality in a South African antiretroviral programme. AIDS 19, 2050-2052 (2005). (Pubitemid 41669038)
100. Lawn SD, Wilkinson RJ, Lipman MC, Wood R. Immune reconstitution and "unmasking" of tuberculosis during antiretroviral therapy. Am. J. Respir. Crit. Care. Med. 177, 680-685 (2008). (Pubitemid 351490554)
101. Goldsack NR, Allen S, Lipman MC. Adult respiratory distress syndrome as a severe immune reconstitution disease following the commencement of highly active antiretroviral therapy. Sex. Transm. Infect. 79, 337-338 (2003). (Pubitemid 37026357)
102. Kranzer K, Houben RM, Glynn JR, Bekker LG, Wood R, Lawn SD. Yield of HIV-associated tuberculosis during intensified case finding in resource-limited settings: a systematic review and meta-analysis. Lancet Infect. Dis. 10, 93-102 (2010).
103. Bassett IV, Wang B, Chetty S et al. Intensive tuberculosis screening for HIV-infected patients starting antiretroviral therapy in Durban, South Africa. Clin. Infect. Dis 51, 823-829 (2010).
104. Lawn SD, Myer L, Edwards D, Bekker LG, Wood R. Short-term and long-term risk of tuberculosis associated with CD4 cell recovery during antiretroviral therapy in South Africa. AIDS 23, 1717-1725 (2009).
105. Lawn SD, Kranzer K, Edwards DJ, McNally M, Bekker LG, Wood R. Tuberculosis during the first year of antiretroviral therapy in a South African cohort using an intensive pretreatment screening strategy. AIDS 24, 1323-1328 (2010).
106. Peter J, Green C, Hoelscher M, Mwaba P, Zumla A, Dheda K. Urine for the diagnosis of tuberculosis: current approaches, clinical applicability, and new developments. Curr. Opin. Pulm. Med. 16, 262-270 (2010).
107. Dheda K, Davids V, Lenders L et al. Clinical utility of a commercial LAM-ELISA assay for TB diagnosis in HIV-infected patients using urine and sputum samples. PLoS ONE 5, e9848 (2010).
108. Pai M, Minion J, Sohn H, Zwerling A, Perkins MD. Novel and improved technologies for tuberculosis diagnosis: progress and challenges. Clin. Chest Med. 30, 701-716 (2009).
109. Helb D, Jones M, Story E et al. Rapid detection of Mycobacterium tuberculosis and rifampin resistance by use of on-demand, near-patient technology. J. Clin. Microbiol. 48, 229-237 (2010).
110. Boehme CC, Nabeta P, Hillemann D et al. Rapid molecular detection of tuberculosis and rifampin resistance. N. Engl. J. Med. 363, 1005-1015 (2010).
111. Lawn SD, Wood R. Tuberculosis screening in patients starting antiretroviral therapy: stretching diagnostics to the limits. Clin. Infect. Dis. 52, 276-277 (2011).
112. Liechty CA, Solberg P, Were W et al. Asymptomatic serum cryptococcal antigenemia and early mortality during antiretroviral therapy in rural Uganda. Trop. Med. Int. Health 12, 929-935 (2007). (Pubitemid 47245826)
113. Karavellas MP, Plummer DJ, Macdonald JC et al. Incidence of immune recovery vitritis in cytomegalovirus retinitis patients following institution of successful highly active antiretroviral therapy. J. Infect. Dis. 179, 697-700 (1999). (Pubitemid 30016157)
114. Nguyen QD, Kempen JH, Bolton SG, Dunn JP, Jabs DA. Immune recovery uveitis in patients with AIDS and cytomegalovirus retinitis after highly active antiretroviral therapy. Am. J. Ophthalmol. 129, 634-639 (2000). (Pubitemid 30323730)
115. Heiden D, Ford N, Wilson D et al. Cytomegalovirus retinitis: the neglected disease of the AIDS pandemic. PLoS Med. 4, e334 (2007).
116. Pathai S, Deshpande A, Gilbert C, Lawn SD. Prevalence of HIV-associated ophthalmic disease among patients enrolling for antiretroviral treatment in India: a cross-sectional study. BMC Infect. Dis. 9, 158 (2009).
117. Meintjes G, Rangaka MX, Maartens G et al. Novel relationship between tuberculosis immune reconstitution inflammatory syndrome and antitubercular drug resistance. Clin. Infect. Dis. 48, 667-676 (2009).
118. Jarvis JN, Harrison TS. HIV-associated cryptococcal meningitis. AIDS 21, 2119-2129 (2007). (Pubitemid 350287209)
119. Brouwer AE, Rajanuwong A, Chierakul W et al. Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial. Lancet 363, 1764-1767 (2004). (Pubitemid 38698379)
120. Bicanic T, Meintjes G, Wood R et al. Fungal burden, early fungicidal activity, and outcome in cryptococcal meningitis in antiretroviral-naive or antiretroviral-experienced patients treated with amphotericin B or fluconazole. Clin. Infect. Dis. 45, 76-80 (2007). (Pubitemid 46984619)
121. Makadzange AT, Ndhlovu CE, Takarinda K et al. Early versus delayed initiation of antiretroviral therapy for concurrent HIV infection and cryptococcal meningitis in sub-saharan Africa. Clin. Infect. Dis. 50, 1532-1538 (2010).
122. Grant PM, Aberg JA, Zolopa AR. Concerns regarding a randomized study of the timing of antiretroviral therapy in Zimbabweans with AIDS and acute cryptococcal meningitis. Clin. Infect. Dis. 51, 984-985 (2010).
123. Boulware DR. Safety, censoring, and intent-to-treat analysis: dangers to generalizability. Clin. Infect. Dis. 51, 985-986 (2010).
124. Brickelmaier M, Lugovskoy A, Kartikeyan R et al. Identification and characterization of mefloquine efficacy against JC virus in vitro. Antimicrob. Agents Chemother. 53, 1840-1849 (2009).
125. Gofton TE, Al-Khotani A, O'Farrell B, Ang LC, McLachlan RS. Mefloquine in the treatment of progressive multifocal leukoencephalopathy. J. Neurol. Neurosurg. Psychiatry DOI:10.1136/jnnp.2009.190652 (2010) (Epub ahead of print).
126. Bassett IV, Wang B, Chetty S et al. Loss to care and death before antiretroviral therapy in Durban, South Africa. J. Acquir. Immune Defic. Syndr. 51, 135-139 (2009).
127. Lawn SD, Torok ME, Wood R. Optimum time to start antiretroviral therapy during HIV-associated opportunistic infections. Curr. Opin. Infect. Dis. 24(1), 34-42 (2010).
128. Zolopa A, Andersen J, Powderly W et al. Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial. PLoS ONE 4, e5575 (2009).
129. Torok ME, Yen NTB, Chau TTH et al. Randomised controlled trial of immediate versus deferred antiretroviral therapy in HIV-associated tuberculous meningitis. Presented at: 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC).San Francisco, CA, USA, 12-15 September (2009) (Abstract H-1224).
130. Marais S, Wilkinson RJ, Pepper DJ, Meintjes G. Management of patients with the immune reconstitution inflammatory syndrome. Curr. HIV/AIDS Rep. 6, 162-171 (2009).
131. Meintjes G, Wilkinson RJ, Morroni C et al. Randomized placebo-controlled trial of prednisone for paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome. AIDS 24, 2381-2390 (2010).
132. Thwaites GE, Nguyen DB, Nguyen HD et al. Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults. N. Engl. J. Med. 351, 1741-1751 (2004).
133. + cell rises in HIV-infected patients. PLoS ONE 5, e13188 (2010).
134. Turner JE, Steinmetz OM, Stahl RA, Panzer U. Targeting of Th1-associated chemokine receptors CXCR3 and CCR5 as therapeutic strategy for inflammatory diseases. Mini Rev. Med. Chem. 7, 1089-1096 (2007). (Pubitemid 350217999)
135. Martin-Blondel G, Cuzin L, Delobel P et al. Is maraviroc beneficial in paradoxical progressive multifocal leukoencephalopathy-immune reconstitution inflammatory syndrome management? AIDS 23, 2545-2546 (2009).
136. Baeke F, Takiishi T, Korf H, Gysemans C, Mathieu C. Vitamin D: modulator of the immune system. Curr. Opin. Pharmacol. 10, 482-496 (2010).
137. Greenwood J, Steinman L, Zamvil SS. Statin therapy and autoimmune disease: from protein prenylation to immunomodulation. Nat. Rev. Immunol. 6, 358-370 (2006).
138. Sun HY, Singh N. Potential role of statins for the management of immune reconstitution syndrome. Med. Hypotheses 76(3), 307-310 (2010).
139. Elliott AM, Halwiindi B, Bagshawe A et al. Use of prednisolone in the treatment of HIV-positive tuberculosis patients. Q. J. Med. 85, 855-860 (1992). (Pubitemid 23012378)
140. Elliott AM, Luzze H, Quigley MA et al. A randomized, double-blind, placebo-controlled trial of the use of prednisolone as an adjunct to treatment in HIV-1- associated pleural tuberculosis. J. Infect. Dis. 190, 869-878 (2004). (Pubitemid 39120962)
141. Volkow PF, Cornejo P, Zinser JW, Ormsby CE, Reyes-Teran G. Life-threatening exacerbation of Kaposi's sarcoma after prednisone treatment for immune reconstitution inflammatory syndrome. AIDS 22, 663-665 (2008). (Pubitemid 351640603)